Alfaxalone (Alfaxan)

Alfaxalone, marketed under the brand name Alfaxan, is a neuroactive steroid anesthetic agent that has become one of the most widely used injectable anesthetics in feline veterinary medicine. This medication belongs to a unique class of anesthetic drugs that work by modulating gamma-aminobutyric acid (GABA) receptors in the central nervous system, producing rapid and reliable anesthesia with an excellent safety profile. Alfaxalone has gained significant popularity in veterinary practices worldwide due to its predictable effects, smooth induction characteristics, and favorable recovery profile in cats. The drug represents a significant advancement over older anesthetic agents, offering veterinarians a versatile tool for both routine procedures and more complex surgical interventions.

The mechanism of action of alfaxalone involves positive modulation of GABA-A receptors in the brain and spinal cord. When alfaxalone binds to these receptors, it enhances the inhibitory effects of GABA, the primary inhibitory neurotransmitter in the mammalian central nervous system. This enhanced inhibition results in decreased neuronal excitability, leading to sedation, muscle relaxation, and ultimately unconsciousness at appropriate doses. Unlike some other anesthetic agents, alfaxalone produces anesthesia through a mechanism similar to naturally occurring neurosteroids, which contributes to its smooth onset and recovery characteristics. The duration of action is relatively short, typically lasting fifteen to twenty minutes following a single induction dose, which allows for precise control of anesthetic depth.

Alfaxalone is available as a clear, aqueous injectable solution containing ten milligrams per milliliter of the active ingredient. The current formulation uses sulfobutylether-beta-cyclodextrin as a solubilizing agent, which has replaced the older cremophor-based formulation that was associated with histamine release and anaphylactic reactions. This newer formulation demonstrates excellent safety and tolerability in cats, with minimal cardiovascular depression and rapid metabolism. The drug can be administered intravenously for rapid induction of anesthesia or intramuscularly when intravenous access is not immediately available or practical. Cats typically experience smooth transitions into and out of anesthesia, with minimal excitement or dysphoria during recovery.

The safety profile of alfaxalone in cats is considered excellent when administered by trained veterinary professionals following appropriate protocols. The drug undergoes rapid hepatic metabolism and is cleared from the body relatively quickly, contributing to its smooth recovery characteristics. However, like all anesthetic agents, alfaxalone requires careful patient assessment, appropriate monitoring during the anesthetic period, and proper supportive care. Veterinary supervision is absolutely essential, as anesthesia carries inherent risks that must be managed by trained professionals with access to monitoring equipment and emergency drugs. Cat owners should understand that while alfaxalone is considered one of the safer anesthetic options available, the decision to anesthetize any patient should be made carefully following thorough pre-anesthetic evaluation.

The primary indication for alfaxalone in feline patients is the induction and maintenance of general anesthesia for surgical and diagnostic procedures. Anesthesia induction refers to the transition from a conscious, awake state to a state of unconsciousness suitable for medical intervention. Alfaxalone excels in this role due to its rapid onset of action when administered intravenously, typically producing unconsciousness within sixty seconds of injection. This rapid, smooth induction minimizes stress for both the patient and the veterinary team, allowing for quick progression to intubation and maintenance of anesthesia with inhalant agents. The drug's reliability and predictability have made it a first-line choice for anesthetic induction in many veterinary practices.

Beyond induction, alfaxalone is frequently used for maintenance of anesthesia during shorter procedures. When given as repeated small boluses or as a continuous rate infusion, alfaxalone can maintain adequate anesthetic depth for procedures lasting up to thirty minutes or longer without the need for inhalant anesthetics. This total intravenous anesthesia approach is particularly valuable in situations where inhalant anesthesia is not available, not practical, or contraindicated. Procedures commonly performed under alfaxalone maintenance include dental cleanings, wound repairs, abscess drainage, and placement of urinary catheters. The drug's short duration of action allows for rapid recovery once administration ceases, which is advantageous for outpatient procedures.

Alfaxalone has become increasingly popular for sedation and chemical restraint in cats requiring diagnostic imaging procedures. Computed tomography scans, magnetic resonance imaging, and radiographic studies often require patients to remain completely still for extended periods, which is challenging to achieve in conscious cats. Alfaxalone provides reliable immobilization with minimal cardiovascular effects, making it suitable for imaging studies where patient stability is important for image quality and patient safety. The drug can be titrated to effect, allowing veterinarians to achieve the precise level of sedation needed for each individual patient and procedure type.

The use of alfaxalone extends to emergency and critical care settings where rapid, safe anesthesia induction is crucial. Cats presenting with trauma, respiratory distress requiring intubation, or other emergency conditions benefit from alfaxalone's rapid onset and relatively minimal cardiovascular depression compared to some alternative agents. The drug is also valuable for cesarean section procedures in pregnant cats, as it has minimal effects on neonatal viability when used appropriately. Kittens delivered from queens anesthetized with alfaxalone typically demonstrate good vigor and rapid recovery, making it a preferred choice for this specialized application.

Veterinarians may select alfaxalone over other injectable anesthetics for several reasons specific to individual patients or clinical situations. Cats with cardiovascular disease may benefit from alfaxalone's relatively mild effects on heart function compared to some alternatives. Patients with hepatic compromise may still be candidates for alfaxalone anesthesia, though careful dose adjustment is required. The drug's lack of histamine release in the current formulation makes it suitable for patients with a history of allergic reactions or mast cell disease. Additionally, alfaxalone's smooth recovery characteristics make it particularly appropriate for fractious or anxious cats, as dysphoric or excited recoveries can be dangerous for both patients and handlers.

The administration of alfaxalone is exclusively performed by licensed veterinary professionals in clinical settings equipped with appropriate monitoring and emergency support capabilities. Cat owners do not administer this medication at home, as it requires intravenous or intramuscular injection techniques, careful dose calculation, and continuous patient monitoring throughout the anesthetic period. Understanding the general principles of alfaxalone dosing helps cat owners appreciate the careful planning and expertise involved in anesthetizing their feline companions. The veterinary team considers numerous factors when determining the appropriate dose for each individual patient.

Intravenous administration is the preferred route for anesthetic induction, as it provides the most rapid and predictable onset of action. The typical induction dose ranges from one to three milligrams per kilogram of body weight, administered slowly over approximately sixty seconds. Veterinarians often use a technique called titration to effect, where the drug is given in small increments until the desired level of anesthesia is achieved. This approach allows for individual variation in drug sensitivity and minimizes the risk of overdose. The exact dose required depends on the patient's health status, concurrent medications, and the depth of anesthesia needed for the planned procedure. Pre-medication with sedatives or analgesics typically reduces the induction dose requirement significantly.

When intravenous access is not immediately available or practical, alfaxalone can be administered via intramuscular injection. This route is commonly used for fractious cats that cannot be safely restrained for intravenous catheter placement, or in field situations where establishing intravenous access before sedation is not feasible. Intramuscular doses are generally higher than intravenous doses, typically ranging from two to five milligrams per kilogram, to account for slower and less complete absorption. The onset of action following intramuscular administration is slower, usually five to fifteen minutes, and the peak effect may be less predictable than with intravenous administration.

For maintenance of anesthesia, alfaxalone can be given as intermittent boluses or as a continuous rate infusion. When using bolus dosing, small increments of approximately one-quarter to one-half of the induction dose are given as needed to maintain adequate anesthetic depth. Continuous rate infusions provide more stable plasma concentrations and smoother anesthesia, typically administered at rates between six and twelve milligrams per kilogram per hour following induction. The infusion rate is adjusted based on the patient's response and the stimulation level of the procedure being performed. Monitoring parameters including jaw tone, eye position, and response to surgical stimulation guide dose adjustments.

The importance of accurate patient weight cannot be overstated when calculating alfaxalone doses. Even small errors in weight estimation can result in significant under- or over-dosing, potentially leading to inadequate anesthesia or excessive cardiorespiratory depression. Most veterinary practices weigh patients on calibrated scales immediately before anesthetic procedures to ensure accurate dosing. Additionally, the patient's body condition score and overall health status influence dose selection, as debilitated or geriatric patients may require reduced doses due to altered drug distribution and metabolism.

Recovery from alfaxalone anesthesia typically occurs within ten to thirty minutes following cessation of drug administration, depending on the total dose given and the duration of anesthesia. Cats should be allowed to recover in a quiet, warm environment with continuous monitoring until they are able to maintain sternal recumbency and normal protective reflexes. The veterinary team monitors recovery closely, as rare cases of prolonged recovery or emergence delirium may require intervention. Cat owners should expect their pet to appear groggy or uncoordinated for several hours following anesthesia and should follow all post-anesthetic care instructions provided by their veterinary team.

Alfaxalone is generally well-tolerated in healthy cats when administered appropriately by trained veterinary professionals, with a side effect profile that compares favorably to other injectable anesthetic agents. However, as with any anesthetic medication, certain adverse effects can occur, and understanding these possibilities helps veterinary teams prepare for and manage complications should they arise. The overall incidence of significant side effects is relatively low when proper patient selection, dosing, and monitoring protocols are followed.

The most commonly observed effects during alfaxalone anesthesia relate to expected pharmacological actions of the drug on the central nervous and cardiovascular systems. Respiratory depression is dose-dependent and predictable, with higher doses causing more pronounced decreases in respiratory rate and tidal volume. At typical induction doses, mild to moderate respiratory depression occurs in most patients, which is usually well-tolerated but may require supportive intervention in some cases. Veterinary teams routinely monitor oxygen saturation and respiratory parameters, providing supplemental oxygen and ventilatory support as needed. Brief periods of apnea immediately following rapid intravenous injection are not uncommon and typically resolve spontaneously or with minimal intervention.

Cardiovascular effects of alfaxalone are generally mild compared to some other anesthetic agents, which is one reason for its popularity in feline practice. Transient decreases in blood pressure and heart rate may occur following induction, particularly if the drug is administered rapidly or at higher doses. These effects are usually modest and well-tolerated in healthy patients but may be more significant in cats with pre-existing cardiovascular disease or hypovolemia. Veterinary teams monitor heart rate, rhythm, and blood pressure throughout anesthetic procedures and are prepared to provide cardiovascular support if needed. The drug does not appear to sensitize the heart to catecholamine-induced arrhythmias, which is advantageous in stress situations.

During recovery from alfaxalone anesthesia, some cats may exhibit transient behavioral changes including vocalization, paddling movements, or apparent disorientation. These emergence phenomena are generally mild and self-limiting, resolving as the drug is cleared from the body. Providing a quiet, dimly lit recovery area helps minimize emergence excitement. Rarely, more pronounced emergence delirium may occur, characterized by thrashing, vocalization, or apparent distress. This can usually be managed with small doses of sedative medications if necessary. Recovery quality is generally better when appropriate pre-anesthetic sedation protocols are used, as these medications help smooth the transition back to consciousness.

Serious adverse effects with alfaxalone are uncommon but can occur. Severe respiratory depression or apnea requiring prolonged ventilatory support is possible, particularly with rapid administration or overdose. While the current cyclodextrin-based formulation has largely eliminated the allergic reactions associated with older cremophor-based products, rare hypersensitivity reactions remain possible with any injectable medication. Signs of allergic reaction may include facial swelling, hives, difficulty breathing, or cardiovascular collapse and require immediate emergency intervention. Veterinary facilities are equipped with emergency drugs and equipment to manage such reactions should they occur. Extravasation of the drug during intravenous injection can cause local tissue irritation, though this is generally minor compared to some other injectable anesthetics.

Alfaxalone should not be administered to cats with known hypersensitivity to the drug or any components of its formulation. While true allergic reactions to alfaxalone itself are rare, cats that have experienced adverse reactions during previous exposure should not receive the drug again. This includes cats that developed signs of anaphylaxis, severe cardiovascular depression, or other unexpected severe reactions following alfaxalone administration. The cyclodextrin solubilizing agent in the current formulation is generally well-tolerated, but hypersensitivity to this component is theoretically possible. Complete disclosure of any previous anesthetic complications to the veterinary team is essential for appropriate drug selection.

Cats with severe hepatic dysfunction may be poor candidates for alfaxalone anesthesia, as the drug relies primarily on hepatic metabolism for elimination. Impaired liver function can result in prolonged drug effects, delayed recovery, and increased risk of accumulation with repeated dosing. Cats with diagnosed liver disease, elevated liver enzymes, or clinical signs of hepatic failure require careful evaluation before anesthesia with any agent. Alternative anesthetic protocols or significant dose reductions may be necessary in these patients. Your veterinarian will assess liver function through blood work and clinical examination before determining the most appropriate anesthetic plan.

Significant cardiovascular compromise represents a relative contraindication to alfaxalone use, depending on the severity and nature of the cardiac condition. While alfaxalone produces less cardiovascular depression than some alternatives, it is not devoid of hemodynamic effects. Cats with severe heart failure, significant arrhythmias, or hemodynamic instability may experience dangerous exacerbation of their condition under anesthesia. However, in many cases of cardiac disease, alfaxalone may actually be preferred over other agents due to its relatively mild cardiovascular effects. The decision requires careful case-by-case evaluation by the veterinary team, often with input from veterinary cardiologists in complex cases.

Pregnancy and lactation require special consideration when alfaxalone use is contemplated. While alfaxalone is considered relatively safe for cesarean section procedures and has demonstrated good neonatal outcomes, routine anesthesia of pregnant cats should be avoided when possible due to the inherent risks of any anesthetic event during pregnancy. Lactating queens can receive alfaxalone when medically necessary, though temporary cessation of nursing may be recommended following the procedure. Very young kittens may have immature hepatic enzyme systems, potentially affecting alfaxalone metabolism and clearance. Geriatric cats often have decreased organ function that affects drug handling and typically require reduced doses. Complete health history, including reproductive status and age, should always be disclosed to the veterinary team.

The concurrent use of other central nervous system depressants significantly affects alfaxalone dosing requirements and must be carefully considered by the veterinary team. Pre-anesthetic medications including sedatives such as dexmedetomidine, acepromazine, or benzodiazepines substantially reduce the dose of alfaxalone needed for induction, often by fifty percent or more. While these drug combinations are commonly used intentionally to provide balanced anesthesia and reduce individual drug doses, failure to account for these interactions could result in dangerous over-sedation or cardiovascular depression. Opioid analgesics similarly enhance alfaxalone's effects and require appropriate dose adjustments. The veterinary team carefully plans multi-drug protocols to take advantage of these synergistic effects while minimizing risks.

Interactions with drugs affecting hepatic metabolism deserve consideration, as alfaxalone undergoes extensive hepatic biotransformation. Drugs that inhibit hepatic enzymes may slow alfaxalone metabolism, potentially prolonging its effects and recovery time. Conversely, drugs that induce hepatic enzymes might theoretically accelerate alfaxalone metabolism, though the clinical significance of this interaction in the acute setting of anesthesia is likely minimal. Cats receiving chronic medications that affect liver function should have this information included in their pre-anesthetic assessment. Common feline medications including certain antibiotics, antifungals, and anti-seizure drugs may influence hepatic enzyme activity.

The combination of alfaxalone with other injectable anesthetics requires particular caution and expertise. While multi-agent anesthetic protocols are common in veterinary practice, the combined effects on cardiovascular and respiratory function can be significant. Ketamine combinations are sometimes used, though the specific benefits and risks of such combinations should be evaluated for each patient. Propofol and alfaxalone have similar mechanisms and recovery profiles, and their combination offers few advantages over either drug alone while potentially increasing the risk of cumulative overdose. The veterinary anesthetist selects drug combinations based on the specific needs of the patient and procedure.

Cat owners should inform the veterinary team of all medications, supplements, and herbal products their cat receives, even if they seem unrelated to the planned procedure. Some herbal supplements can affect cardiovascular function, bleeding, or drug metabolism in ways that may complicate anesthesia. Certain supplements should be discontinued prior to anesthetic procedures to minimize potential interactions. Over-the-counter medications given to cats without veterinary guidance can also pose interaction risks and should be disclosed. Complete medication history allows the veterinary team to plan the safest possible anesthetic protocol for each individual patient.

Alfaxalone should only be administered in facilities equipped with appropriate monitoring equipment, oxygen supplementation capabilities, and emergency drugs and supplies. The veterinary team monitors multiple parameters throughout the anesthetic period, including heart rate and rhythm, blood pressure, oxygen saturation, respiratory rate and pattern, and body temperature. Continuous monitoring allows for early detection of complications and prompt intervention when needed. Cat owners should ensure their veterinary facility follows current monitoring standards and can provide the level of care their pet requires.

Accurate patient weight is critical for safe alfaxalone dosing, as the drug is dosed on a milligram per kilogram basis. Overestimation of weight can lead to overdose with excessive cardiorespiratory depression, while underestimation may result in inadequate anesthesia or awareness during procedures. Most practices weigh patients on the day of the procedure using calibrated scales. Body condition should also be assessed, as obese patients have altered drug distribution and may require dose adjustment based on lean body weight rather than total body weight. Similarly, cachectic or dehydrated patients may be more sensitive to standard doses.

Certain cat breeds may exhibit variations in drug sensitivity that warrant consideration during anesthetic planning. While specific breed sensitivities to alfaxalone are not as well-documented as with some other drugs, individual variation in drug response exists within all breeds. Brachycephalic breeds such as Persians and Himalayans have anatomical features that increase anesthetic risk related to airway management rather than drug sensitivity per se. These cats may require additional airway support and monitoring during recovery. Any previous anesthetic complications in the individual patient or close relatives should be reported to the veterinary team.

Environmental and handling precautions during alfaxalone administration protect both patients and veterinary staff. The drug should be handled aseptically, and any unused portion of opened vials should be discarded according to the manufacturer's recommendations and facility protocols. In multi-cat households where one pet undergoes anesthesia, the recovering patient should be separated from housemates until fully recovered to prevent injury from uncoordinated movements or inappropriate interactions. The recovering cat should be kept in a safe, confined area away from stairs, elevated surfaces, or other hazards until fully alert and ambulatory.

Special populations require additional consideration when alfaxalone anesthesia is planned. Geriatric cats often have decreased hepatic and renal function affecting drug metabolism and excretion, typically necessitating dose reductions of twenty to thirty percent or more. Young kittens may have immature hepatic enzyme systems and also require careful dose adjustment. Cats with chronic diseases including diabetes, hyperthyroidism, or inflammatory conditions may have altered physiological status affecting anesthetic risk and drug handling. Pre-anesthetic blood work and physical examination help identify these patients and guide appropriate protocol modifications.

Alfaxalone (Alfaxan) should be stored according to manufacturer specifications to maintain drug stability and efficacy. The product should be kept at controlled room temperature, typically between fifteen and thirty degrees Celsius (59 to 86 degrees Fahrenheit), protected from light and temperature extremes. The medication should not be frozen, as this may affect the cyclodextrin formulation and potentially alter drug solubility or stability. Veterinary facilities store alfaxalone in medication storage areas that maintain appropriate temperature and protect the product from direct sunlight. Cat owners do not handle or store this medication, as it is administered only by veterinary professionals.

Once a vial of alfaxalone is opened, the remaining contents have a limited shelf life that varies by manufacturer recommendations. The current formulation does not contain preservatives, which limits the duration that opened vials can be safely used. Many practices follow policies of single-use or same-day use of opened vials to minimize contamination risk and ensure drug stability. Veterinary teams should inspect the solution before each use, verifying that it remains clear and free of particulate matter or discoloration. Any vials showing visible changes should be discarded even if within the labeled expiration period. Proper documentation of vial opening dates helps ensure compliance with storage guidelines.

As a Schedule IV controlled substance in many jurisdictions, alfaxalone is subject to specific handling, documentation, and security requirements. Veterinary facilities must maintain accurate records of alfaxalone acquisition, use, and disposal in compliance with applicable regulations. The drug must be stored in locked cabinets or other secure storage appropriate for controlled substances. These regulations exist to prevent drug diversion and ensure appropriate use of anesthetic agents. Veterinary professionals are trained in controlled substance handling and documentation requirements.

Proper disposal of unused alfaxalone and used injection equipment follows hazardous waste and controlled substance disposal regulations. Sharps including needles and syringes used for drug administration are disposed of in approved sharps containers. Unused drug product is disposed of according to controlled substance regulations, which may include documented destruction or return to licensed reverse distributors. Veterinary facilities have established protocols for pharmaceutical waste disposal that comply with local, state, and federal regulations. These procedures protect the environment and prevent potential misuse of discarded medications.

Most cat breeds tolerate alfaxalone anesthesia similarly, with individual patient factors generally playing a more significant role in anesthetic response than breed alone. However, veterinary anesthetists remain aware of potential breed-related variations in drug sensitivity, physiology, and disease predispositions that may influence anesthetic planning and management. A thorough pre-anesthetic assessment considers breed alongside other patient factors including age, weight, health status, and planned procedure.

Brachycephalic breeds including Persians, Himalayans, Exotic Shorthairs, and British Shorthairs present unique anesthetic considerations related to their airway anatomy rather than specific sensitivity to alfaxalone itself. These breeds have shortened skulls and compressed airways that can make intubation more challenging and increase the risk of airway obstruction during recovery. Vigilant airway monitoring and extended recovery supervision are particularly important for brachycephalic patients. The smooth recovery characteristics of alfaxalone may actually be advantageous in these breeds, as excitement or struggling during emergence can exacerbate airway compromise. Veterinary teams experienced with brachycephalic patients take appropriate precautions regardless of the anesthetic agent used.

Certain purebred cats have increased prevalence of cardiac disease that influences anesthetic risk assessment. Maine Coons, Ragdolls, and British Shorthairs have elevated incidence of hypertrophic cardiomyopathy, while other breeds may be predisposed to different cardiac conditions. Pre-anesthetic cardiac evaluation, potentially including echocardiography, may be recommended for breeds with known cardiac disease predispositions or for individual cats with detected murmurs or arrhythmias. While alfaxalone's relatively mild cardiovascular effects make it a reasonable choice for many cardiac patients, the decision requires careful individual assessment. Breed-associated cardiac risks should be discussed with the veterinary team before any anesthetic procedure.

Size variations between cat breeds affect practical aspects of alfaxalone dosing and administration. Large breeds such as Maine Coons and Norwegian Forest Cats may require different syringe sizes or administration techniques compared to smaller breeds like Singapura or Devon Rex. Very small patients require precise dose measurement, as even small volume errors represent significant percentage dose variations. The veterinary team selects appropriate equipment and techniques based on patient size to ensure accurate, safe drug administration. Regardless of breed or size, accurate weight measurement and careful dose calculation remain essential for safe anesthesia.

Several other injectable anesthetic agents are available for feline patients, each with distinct characteristics that may make them more or less suitable for specific situations. Propofol is another commonly used induction agent with similarly rapid onset and recovery, though it may produce more cardiovascular depression in some patients. Ketamine produces dissociative anesthesia and is often used in combination with sedatives or benzodiazepines, offering good analgesia but potentially rougher recovery characteristics. The choice between these agents depends on patient factors, procedure requirements, and veterinary preference and experience.

Within the category of neuroactive steroid anesthetics, alfaxalone currently represents the primary option available in veterinary medicine. Older formulations of alphaxalone-alphadolone (Saffan) are no longer available in most markets due to adverse reactions associated with the cremophor-based solubilization system. The current cyclodextrin-based alfaxalone formulation has largely replaced these older products and offers improved safety. Research continues into other neuroactive steroid compounds, but alfaxalone remains the established choice in this drug class for veterinary patients.

Inhalant anesthetics including isoflurane and sevoflurane represent alternative approaches to anesthetic maintenance and are often used in conjunction with alfaxalone for induction. Following alfaxalone induction, patients are commonly transitioned to inhalant anesthetics delivered through an endotracheal tube for longer procedures. This approach combines the smooth induction characteristics of alfaxalone with the precise control and easy reversibility of inhalant maintenance. The choice between total intravenous anesthesia with alfaxalone and inhalant maintenance depends on procedure duration, available equipment, and patient factors.

Complementary medications used alongside alfaxalone enhance overall anesthetic quality and patient comfort. Pre-anesthetic sedatives reduce anxiety and alfaxalone dose requirements while smoothing induction and recovery. Opioid analgesics provide pain control that pure anesthetics like alfaxalone do not offer. Anticholinergic drugs may be used to prevent bradycardia or excessive salivation. The veterinary anesthetist selects complementary medications based on individual patient needs, creating a balanced anesthetic protocol tailored to each situation. Any decisions about alternative anesthetic agents or protocols should be made by qualified veterinary professionals based on thorough patient assessment.